ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Vivoryon Therapeutics Nv

Vivoryon Therapeutics Nv (0R3M)

4.71
0.00
(0.00%)
終了 2月6日 1:30AM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

通貨
4.71
買値
0.00
売値
0.00
出来高
32
0.00 日の範囲 0.00
4.71 52 週間の範囲 4.71
時価総額
前日終値
4.71
始値
-
最終取引時間
財務取引量
-
VWAP
-
平均取引量 (3 か月)
3,933
発行済株式数
0.00
配当利回り
-
PER
0.00
1 株当たり利益 (EPS)
-
歳入
-3.62M
純利益
-28.34M

Vivoryon Therapeutics Nv について

セクター
Biological Pds,ex Diagnstics
業界
Biological Pds,ex Diagnstics
ウェブサイト
本社
Halle, Deu
設立
-
Vivoryon Therapeutics Nv is listed in the Biological Pds,ex Diagnstics sector of the ロンドン証券取引所 with ticker 0R3M. The last closing price for Vivoryon Therapeutics Nv was 4.71 €. Over the last year, Vivoryon Therapeutics Nv shares have traded in a share price range of 4.71 € to 4.71 €.

Vivoryon Therapeutics Nv currently has 0 shares in issue.

0R3M 最新ニュース

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function Vivoryon Therapeutics N.V. Presents Topline Phase...

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress...

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of...

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon...

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Vivoryon Therapeutics N.V...

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and...

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial...

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in...

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1004.714.714.711224.71DE
4004.714.714.715364.71DE
12004.714.714.7139334.71DE
26004.714.714.7140204.71DE
52004.714.714.71121914.71DE
156004.714.714.7160024.71DE
260004.714.714.7142974.71DE

0R3M - Frequently Asked Questions (FAQ)

What is the current Vivoryon Therapeutics Nv share price?
The current share price of Vivoryon Therapeutics Nv is 4.71 €
What is the 1 year trading range for Vivoryon Therapeutics Nv share price?
Vivoryon Therapeutics Nv has traded in the range of 4.71 € to 4.71 € during the past year
What is the reporting currency for Vivoryon Therapeutics Nv?
Vivoryon Therapeutics Nv reports financial results in EUR
What is the latest annual turnover for Vivoryon Therapeutics Nv?
The latest annual turnover of Vivoryon Therapeutics Nv is EUR -3.62M
What is the latest annual profit for Vivoryon Therapeutics Nv?
The latest annual profit of Vivoryon Therapeutics Nv is EUR -28.34M
What is the registered address of Vivoryon Therapeutics Nv?
The registered address for Vivoryon Therapeutics Nv is WEINBERGWEG 22, HALLE, 06120
What is the Vivoryon Therapeutics Nv website address?
The website address for Vivoryon Therapeutics Nv is www.vivoryon.com
Which industry sector does Vivoryon Therapeutics Nv operate in?
Vivoryon Therapeutics Nv operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
GFINGfinity Plc
0.095p
(72.73%)
576.77M
XSGXeros Technology Group Plc
0.70p
(33.33%)
23.5M
OMIOrosur Mining Inc
9.55p
(29.93%)
11.76M
SNGSynairgen Plc
2.49p
(27.86%)
229.83k
IKAIlika Plc
34.25p
(26.85%)
1.91M
WBIWoodbois Limited
0.0525p
(-36.36%)
546.31M
CRVCraven House Capital Plc
US$ 0.275
(-26.67%)
49.99k
KRPZKropz Plc
0.85p
(-26.09%)
432.89k
MACMarechale Capital Plc
2.35p
(-24.19%)
26.92M
TRCThe Revel Collective Plc
0.175p
(-22.22%)
5.52M
NTVONativo Resources Plc
0.0017p
(0.00%)
2.07B
GFINGfinity Plc
0.095p
(72.73%)
576.77M
WBIWoodbois Limited
0.0525p
(-36.36%)
546.31M
OBDOxford Biodynamics Plc
0.55p
(10.00%)
373.53M
MSMNMosman Oil And Gas Limited
0.04p
(-8.05%)
338.97M